FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Sept. 13, 2006--Andrx Corporation (Nasdaq:ADRX) (“Andrx” or the “Company”) announced today that on September 12, 2006, it certified that each representation and warranty of the Company contained in the merger agreement, as amended, with Watson Pharmaceuticals, Inc. (NYSE:WPI) is true and correct as of September 12, 2006, except as would not have individually or in the aggregate, a material adverse effect and that no material adverse effect has occurred with regard to Andrx or its ability to consummate the merger since March 12, 2006. The merger agreement, as amended, provides that in the event that the representations and warranties made by Andrx in the merger agreement are true and correct on September 12, 2006, then such representations and warranties will be deemed to be true on all dates subsequent to September 12, 2006. In addition, in the event that no material adverse effect has occurred with regard to Andrx or its ability to consummate the merger on September 12, 2006, then if a material adverse effect were to occur after September 12, 2006, such material adverse effect will not affect the consummation of the merger.
